Janus Kinase Inhibitors for the Treatment of Acute Severe Ulcerative Colitis

Recruiting

• Conditions: Ulcerative Colitis; Inflammatory Bowel Diseases

• Registration Number: NCT06449820
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-4-15
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Patient = 18 years old,<br><br> - Established diagnosis of ulcerative colitis as per ECCO (European Crohn´s and<br> Colitis Organisation) criteria,<br><br> - Hospitalisation at any point for treatment of ulcerative colitis disease relapse,<br><br> - Receiving at least one dose of tofacitinib, filgotinib, or upadacitinib for the<br> treatment of severe UC during inpatient stay,<br><br> - Endoscopically confirmed active disease (Mayo endoscopic subscore = 2) within<br> previous four weeks,<br><br> - Patient who has received full information about the organization of the research and<br> who has not objected to his or her participation and to the use of his or her data.<br><br>Exclusion Criteria:<br><br> - Diagnosis of Crohn's disease or unclassified Inflammatory Bowel Disease,<br><br> - Receiving JAKi prior to admission,<br><br> - Clostridium difficile, cytomegalovirus (CMV), or other enteric infections identified<br> on admission.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment failure up to day 98 after JAKi initiation to describe treatment effectiveness